



Published in final edited form as:

*Phytochem Rev.* 2016 June ; 15(3): 425–444. doi:10.1007/s11101-016-9459-z.

## The Chemistry of Gut Microbial Metabolism of Polyphenols

Jan F. Stevens<sup>1,3</sup> and Claudia S. Maier<sup>2,3</sup>

<sup>1</sup>Department of Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon 97330

<sup>2</sup>Department of Chemistry, Oregon State University, Corvallis, Oregon 97330

<sup>3</sup>Linus Pauling Institute, Oregon State University, Corvallis, Oregon 97330

### Abstract

Gut microbiota contribute to the metabolism of dietary polyphenols and affect the bioavailability of both the parent polyphenols and their metabolites. Although there is a large number of reports of specific polyphenol metabolites, relatively little is known regarding the chemistry and enzymology of the metabolic pathways utilized by specific microbial species and taxa, which is the focus of this review. Major classes of dietary polyphenols include monomeric and oligomeric catechins (proanthocyanidins), flavonols, flavanones, ellagitannins, and isoflavones. Gut microbial metabolism of representatives of these polyphenol classes can be classified as A- and C-ring cleavage (retro Claisen reactions), C-ring cleavage mediated by dioxygenases, dehydroxylations (decarboxylation or reduction reactions followed by release of H<sub>2</sub>O molecules), and hydrogenations of alkene moieties in polyphenols, such as resveratrol, curcumin, and isoflavones (mediated by NADPH-dependent reductases). The qualitative and quantitative metabolic output of the gut microbiota depends to a large extent on the metabolic capacity of individual taxa, which emphasizes the need for assessment of functional analysis in conjunction with determinations of gut microbiota compositions.

### Keywords

Catabolism; flavonoid; gut microbiota; mechanism; metabolic pathway

### Introduction

The existence of a relationship between diet and health has been known for centuries. Such relationships have resulted in the discovery of vitamins and minerals to prevent their respective deficiency diseases. In the past several decades, researchers have identified new roles for vitamins beyond prevention of diseases and have proposed doses to achieve optimum health. While dietary polyphenols are generally not recognized as essential components of the diet, epidemiological data do suggest a positive relationship between dietary exposure to polyphenols and health. Earlier work on the health benefits of polyphenols has focused on the hypothesis that polyphenols exert beneficial effects by acting as anti-oxidants in the sense that they scavenge free radical species. Support for the anti-

oxidant hypothesis originated primarily from *in vitro* studies using standard anti-oxidant tests, such as the ORAC and FRAP assays (Cao, Prior, 1998; Huang, Ou, Prior, 2005), at oftentimes supra-physiological concentrations. While these studies have accumulated valuable information on the chemical properties of polyphenols, they have not generated a satisfactory explanation for their beneficial effects in animal models of disease and in humans (Pompella, Sies, Wacker et al., 2014). One well-recognized problem is the discrepancy between micromolar concentrations of polyphenols used in cell culture models to achieve a certain biological effect and the circulating concentrations in animals and humans in the nanomolar range resulting from efficacious doses of polyphenols. Even if polyphenols would reach micromolar concentrations in target cells, they would unlikely be able to compete with the two foremost small-molecule anti-oxidants, ascorbic acid and glutathione, which are both present in cells at low millimolar concentrations.

In addition, many orally administered polyphenols appear in the general circulation primarily as their glucuronides and sulfates, which further complicates the integration of pharmacological data with pharmacokinetic observations. For instance, in our own research on dose-effect relationships of xanthohumol, a prenylated flavonoid from the hops plant, we found poor correlations between circulating levels of xanthohumol and the primary endpoints, i.e., weight gain, fasting plasma glucose, and levels of dysfunctional fatty acid metabolism. However, the circulating levels of glucuronides of xanthohumol correlated well with dose and with the primary endpoints (Legette, Ma, Reed et al., 2012; Legette, Luna, Reed et al., 2013). Many researchers have made similar observations, which, collectively, have shifted the field of polyphenol research towards metabolism of polyphenols, interconversions of metabolites and biological activity of metabolites.

Mammalian metabolic transformations of polyphenols fall by and large into phase 1 and phase 2 metabolism, giving rise to hydroxylation of aromatic rings, *O*-methylation, *O*-demethylation, and conjugation of hydroxy groups to yield glucuronides and sulfates. Electrophilic moieties, such as quinones and  $\alpha,\beta$ -unsaturated carbonyl compounds, are subject to conjugation with glutathione, the product of which is further metabolized to the *N*-acetylcysteine adduct via the mercapturic acid pathway. Polyphenol-derived quinone metabolites can be considered active metabolites in the sense that they have the ability to induce an adaptive stress response by activating the transcription factor Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) (Lee-Hilz, Boerboom, Westphal et al., 2006). Nrf2 is a key regulator that orchestrates the regulation of more than 100 anti-oxidant response element (ARE) genes that encode proteins with cytoprotective functions including heat shock proteins, anti-oxidant proteins, NADPH regenerating enzymes, detoxification enzymes and the principal enzymes involved in the biosynthesis of glutathione (Eggler, Gay, Mesecar, 2008; Kumar, Kim, More et al., 2014). Nrf2 is regulated by Kelch-like ECH-associated protein 1 (Keap1) protein, an unusually cysteine-rich protein that acts as a sensor for reactive oxidative and electrophilic species. Polyphenol-derived quinones function as Michael acceptors to modify distinct cysteine residues on Keap1 (Eggler, Small, Hannink et al., 2009). There is evidence that Keap1 modification by quinone-forming polyphenols leads to Nrf2 activation and expression of ARE genes (Kumar, Kim, More et al., 2014; Lee, Lim, Gal et al., 2011). Protocatechuic acid, a signature metabolite of gut microbial biotransformation of anthocyanins, contains a readily oxidizable 3,4-dihydroxy aromatic ring and is a known

Nrf2 activator (Kumar, Kim, More et al., 2014; Vari, D'Archivio, Filesi et al., 2011). Caffeic acid derivatives are other examples of gut microbial catabolites that have Nrf2 activating properties (Gray, Sampath, Zweig et al., 2015; Ma, Hong, Wang et al., 2010; Rechner, Smith, Kuhnle et al., 2004; Williamson, Clifford, 2010).

In recent years, researchers have identified relationships between compositions of gut microbiota and health (Turnbaugh, Ridaura, Faith et al., 2009; Xu, Gordon, 2003). Such observations raise the question whether dietary polyphenols exert their health effects by changing gut microbiota composition. Alternatively, gut microbiota may alter the pharmacokinetics of dietary polyphenols and may produce bioavailable metabolites whose pharmacological properties are different from those of the parent polyphenols. For example, xanthohumol does not exert demonstrable estrogenic effects in animals and in cell culture models, whereas its metabolite, 8-prenylnaringenin, which can be produced by gut microbiota (Possemiers, Bolca, Grootaert et al., 2006; Possemiers, Heyerick, Robbens et al., 2005), has greater estrogenic potency than the well-known phytoestrogen, genistein (Milligan, Kalita, Pocock et al., 2000). This and other examples cited in this review highlight the impact of gut microbial metabolism of polyphenols on host health.

Gut microbiota influence polyphenol bioavailability by hydrolytic release of aglycones from *O*-glycosides and hepatic *O*-glucuronides. Polyphenols occur primarily as *O*-glycosides in plants and foods. Quercetin and kaempferol, two of the most abundantly and ubiquitously present flavonoids, are predominantly found as their *O*-glycosides. The red, blue, and purple flavonoid pigments of berries are also predominantly found in glycoside form. A large proportion of these glycosides are hydrolytically converted into their corresponding aglycones in the acidic environment of the stomach, the mucosa of the small intestines, and by enzymes expressed by gut microbiota. After absorption in the small intestine, the aglycones reach the liver where they are enzymatically converted into their *O*-glucuronides and *O*-sulfates. A variable proportion of the polyphenol conjugates is excreted in the bile and enters the small intestine. Several gut microbes are known to have glucuronidase capacity and convert polyphenol glucuronides back into their aglycones, available for re-absorption. This enterohepatic recycling scenario demonstrates that gut microbes exerting glycosidase and glucuronidase activity would directly enhance bioavailability of polyphenol glycosides. Using germ-free (GF) and human microbiota-associated (HMA) rats to determine the influence of gut microbiota on polyphenol bioavailability, Hanske and co-workers (Hanske, Loh, Sczesny et al., 2010) found higher amounts of xanthohumol glucuronides excreted in the feces of GF rats given an oral dose of xanthohumol, indicating that human microbiota exert glucuronidase activity. The same research group performed a similar study with apigenin-7-*O*-glucoside and found higher levels of C-ring cleavage products of apigenin in the urine of HMA rats (Hanske, Loh, Sczesny et al., 2009). They also determined that cytosolic extracts of *Eubacterium ramulus* and *Bacteroides distasonis* enzymatically convert apigenin-7-*O*-glucoside into its aglycone. The authors conclude that gut microbiota contribute proportionally the most to metabolism of orally administered apigenin-7-*O*-glucoside (Hanske, Loh, Sczesny et al., 2009). Other researchers have made similar observations with other polyphenols, which generalizes the notion that gut microbiota affect polyphenol bioavailability in major ways.

In addition to enzymatic ability to cleave *O*-glycosides and *O*-glucuronides, gut microbes appear to have metabolic capacity to perform carbon-carbon cleavage of heterocyclic and aromatic rings in flavonoids, dehydroxylations, decarboxylations, and hydrogenation of alkene moieties. Such metabolic transformations do not occur at random but follow a sequence of reactions ruled by basic chemical principles. While there are numerous papers listing microbial metabolites of dietary polyphenols, few studies have focused on the actual metabolic pathways and underlying enzymology responsible for the production of these metabolites. For most of the major dietary polyphenols, the pattern of gut microbial metabolites has been reported. But, how useful is this information if we do not know which microbe species has capacity for what metabolic conversion? In other words, it is equally important to know 'who is there' as to know 'what they do' in the gut. If such knowledge would become available, one would be able to predict the pattern of microbial metabolites based on the composition of the gut microbiome and establish 'enterotypes'. Knowledge of gut microbial pathways of polyphenol metabolism would also enable one to determine whether a metabolite detected in the host is of gut microbial origin.

This review does not intend to provide an exhaustive listing of microbial metabolites of individual polyphenols: such information can easily be obtained by structural searching of metabolites in combination with their parent polyphenols using databases such as SciFinder. What this review does provide is an overview of the chemical mechanisms of gut microbial transformations of the major classes of dietary polyphenols, information which is necessary to construct a plausible metabolic pathway for any given dietary polyphenol. The following gut microbe-mediated reactions are discussed next: 1) carbon-carbon cleavage reactions involving C- and A-rings, 2) dehydroxylations, and 3) hydrogenations.

## Carbon-carbon cleavage reactions

Enzymatic cleavage of C-C bonds in flavonoids appears to be characteristic of gut microbiota. Cleavage can take place in the heterocyclic C-ring of flavonols, flavones, flavanones, and anthocyanidins, as well as in the aromatic ring A of flavanols. The resulting phenolic acids are usually detected in the general circulation or in the urine as major metabolites.

### C-ring cleavage of anthocyanidins

Anthocyanins represent a class of flavonoid plant pigments, responsible for red, purple, and blue colors of flower petals, vegetables, berries and other fruits. Anthocyanins are the glycosylated forms of their corresponding aglycones, anthocyanidins. The estimated daily intake of anthocyanins by U.S. adults is estimated at 200 mg (Wang, Stoner, 2008). While the glycosides are bioavailable (Bitsch, Janssen, Netzel et al., 2004; Bub, Watzl, Heeb et al., 2001; Czank, Cassidy, Zhang et al., 2013; Felgines, Talavera, Gonthier et al., 2003; Mertens-Talcott, Rios, Jilma-Stohlawetz et al., 2008), they are subject to hydrolytic conversion into their corresponding anthocyanidins. Both the glycosides and the aglycones are found as glucuronides in the urine of animals and humans (Ichiyanagi, Shida, Rahman et al., 2008; Kay, Mazza, Holub et al., 2004). Alternatively, the anthocyanidins can be metabolized into protocatechuic acid (Aura, Martin-Lopez, O'Leary et al., 2005). Using cyanidin as the

prototypic anthocyanidin, its metabolism is initiated by opening of the heterocyclic flavylum ring at neutral or slightly basic conditions of the small intestine. Subsequent attack of the flavylum carbon at position 2 produces an instable hemi-ketal that forms a ketone. Through keto-enol tautomerism of the neighboring enol functionality, the resulting  $\alpha$ -diketo moiety can be cleaved by gut microbiota to form protocatechuic acid (**1.6**, Figure 1) and 2-(2,4,6-trihydroxyphenyl)acetic acid (**1.7**). The exact mechanism of the cleavage reaction remains to be elucidated, but it seems reasonable to propose that the C-C cleavage involves attack of either carbonyl by a peroxy anion species, similar to the initial step in the dioxygenase-mediated conversion of  $\alpha$ -ketoglutarate into succinate (Silverman, 2002). Insertion of the resulting alkoxy oxygen between the original carbonyl carbons yields an anhydride, which forms the two phenolic acids upon hydrolysis (Figure 1). This proposed mechanism is also similar to the oxidative conversion of benzoin into benzoic acids (Kang, Joo, Kim et al., 2011). After absorption from the intestinal tract and hepatic phase 2 metabolism, these phenolic acids are usually detected in the urine in unchanged form or as their *O*-glucuronides or *O*-methyl derivatives (Amin, Czank, Raheem et al., 2015; Wang, Xia, Yan et al., 2012; Woodward, Needs, Kay, 2011).

### C-ring cleavage of flavonols

Quercetin, the prototypic representative of the large group of flavonols, has a virtually ubiquitous distribution among flowering plants. It is present in most if not all fruits and vegetables, predominantly in the form of *O*-glycosides. Several studies of metabolism of quercetin or its glycosides by fecal microbiota have revealed the conversion of quercetin into protocatechuic acid (**2.6**) (Serra, Macia, Romero et al., 2012) and 2-(3,4-dihydroxy)-phenylacetic acid (**4.4**) (Hein, Rose, van't Slot et al., 2008; Peng, Zhang, Zhang et al., 2014; Schneider, Simmering, Hartmann et al., 2000) as the major metabolites. These metabolites can be further transformed into their *O*-methyl metabolites (Chadwick, George, Claxton, 1992). The enzymatic release of protocatechuic acid from quercetin can be mediated by fungal and bacterial quercetin dioxygenases, also referred to as quercetinases (Hirooka, Fujita, 2010; Schaab, Barney, Francisco, 2006) (Table 1). They may contain iron, copper, or manganese in their catalytic site (Sun, Huang, Li et al., 2015). Several authors have proposed a mechanism for the reaction, which have in common that a metal ion chelates the oxygen atoms at positions 3 and 4 in quercetin and that the mechanism involves a superoxide or peroxy species (Fetzner, 2012; Hirooka, Fujita, 2010). In addition, carbon 3 of quercetin is released as carbon monoxide.

The consensus mechanism of quercetinase is initiated by chelation of the 4-keto/2,3-enol moiety by a divalent cation in the enzyme, which appears to favor the 3,4-diketo tautomer. The metal ion-bound flavonol complex sets the hydrogen atom at position 2 up for abstraction, conceivably via a semi-quinone species formed from a B-ring phenoxy radical. The carbon 2-centered radical then reacts with superoxide to form a five-membered endo-peroxide (Figure 2, steps i and ii). In steps iii and iv, rearrangement of the endo-peroxide, initiated by conversion of the 3-keto into an acylium group, results in an ester linking the two aromatic rings, a carboxylic acid group at ring A, and release of carbon monoxide. While quercetin dioxygenases yield 2-protocatechuoyl-phloroglucinol carboxylic acid (Figure 2, compound **2.5**) in enzyme incubations or in incubations with microbiota, it has

not been reported as a metabolite of quercetin in animals or humans, conceivably due to hydrolytic cleavage of the ester into protocatechuic acid (**2.6**) and 2,4,6-trihydroxybenzoic acid (**2.7**). Furthermore, there are no reports of the degradation product **2.7** as a metabolite of quercetin, but decarboxylation would explain the formation of the known gut microbial metabolite of quercetin, phloroglucinol (Ulbrich, Reichardt, Braune et al., 2015).

The dependence on molecular oxygen in quercetinase- and other dioxygenase-mediated metabolic conversions raises the question how these microbial reactions can occur in the virtually anoxic environment of the gut. The gut epithelium separates the near-anoxic gut lumen from the highly vascularized and oxygen-rich sub-epithelium (Heinken, Thiele, 2015; Taylor, Colgan, 2007). Blood vessels in sub-epithelial tissue of the intestine facilitate efficient nutrient uptake, but they also supply oxygen to the epithelium and indirectly to the gut lumen by diffusion. The resulting steep oxygen gradient across the epithelial cell layer poses stress on both the epithelium and on obligate anaerobic micro-organisms in the gut lumen. Facultative anaerobic micro-organisms may survive or even thrive at this oxic/anoxic interface without interference from obligate anaerobes. Previously documented as an aerobic soil microbe, *Bacillus subtilis* has gained a new status as a facultative anaerobe (Hoffmann, Troup, Szabo et al., 1995). Moreover, its isolation from and behavior in the human intestinal tract led some researchers to consider *B. subtilis* as a normal gut commensal in humans (Hong, Khaneja, Tam et al., 2009). Quercetinase from *B. subtilis* has been overexpressed in *E. coli*, isolated and biochemically characterized (Bowater, Fairhurst, Just et al., 2004; Schaab, Barney, Francisco, 2006). Therefore, *B. subtilis* is a possible quercetinase-dependent producer of protocatechuic acid from dietary quercetin in the human gut.

As a major gut microbial metabolite of anthocyanidins and quercetin, protocatechuic acid contributes to health effects of fruits and vegetables rich in these flavonoids due to its reported anti-inflammatory (Kakkar, Bais, 2014; Masella, Santangelo, D'Archivio et al., 2012), anti-glycemic (Harini, Pugalendi, 2010), and cancer chemopreventive effects (Lin, Chen, Chou et al., 2011; Peiffer, Zimmerman, Wang et al., 2014; Tsao, Hsia, Yin, 2014; Yin, Lin, Wu et al., 2009).

### A-ring cleavage of catechin: Reverse Claisen reactions

Catechin and its 3-epimer, epicatechin, are flavan-3-ol constituents of many fruits, such as apples and grapes. The gallic acid ester of epigallocatechin at position 3, epigallocatechin-3-*O*-gallate (EGCG), is an abundant flavanol in green tea. In addition, (epi)catechin forms oligomers, termed proanthocyanidins or condensed tannins, which give many fruits and especially unripe fruits, an astringent taste. Monomeric and oligomeric catechins constitute a prominent group of dietary flavonoids, and their total daily intake has been estimated to exceed 50 mg for adults. The major sources of dietary proanthocyanidins are apples, chocolate, and grapes in the U.S. (Gu, Kelm, Hammerstone et al., 2004). While the monomeric, dimeric, and trimeric catechins are absorbed from the small intestine to some extent, the higher oligomers are very poorly or not bioavailable (Rasmussen, Frederiksen, Struntze Krogholm et al., 2005). Spencer and co-workers (Spencer, Chaudry, Pannala et al., 2000) have demonstrated that proanthocyanidins undergo partial acid-catalyzed cleavage into their monomeric flavan-3-ol units in the gastric milieu. However, others have disputed

the contribution of gastric depolymerization to the bioavailability of the constituent catechin units of proanthocyanidins (Donovan, Manach, Rios et al., 2002).

The major gut microbial metabolites of monomeric and oligomeric catechins appear to be 3-hydroxyphenylacetic acid, 3-hydroxyphenylpropionic acid, 3,4-dihydroxyphenylacetic acid (**4.4**), and 3-hydroxyphenyl- $\gamma$ -valerolactone (**3.13**) (Appeldoorn, Vincken, Aura et al., 2009). The latter metabolite is an example of an A-ring cleavage achieved by two consecutive reverse Claisen reactions (Figure 3, steps iv through viii). Opening of the C-ring, possibly involving a quinone-methide intermediate (**3.2**), sets the stage for retro Claisen cleavage. At this point in the catabolism of catechin, there are two possibilities: 1) reduction of the quinone carbonyl yields the corresponding *p*-hydroxy metabolite, which is subject to dehydroxylation (Figure 3, step iii), and 2) the quinone carbonyl is not reduced and hydride attack at the methide carbon yields a 3,4-dihydroxyphenyl metabolite which would eventually give rise to 3,4-dihydroxyphenyl- $\gamma$ -valerolactone. Several authors have reported the latter compound as a product of gut microbial metabolism (Barroso, Sanchez-Patan, Martin-Alvarez et al., 2013, Goodrich, Neilson, 2014, Jimenez-Giron, Ibanez, Cifuentes et al., 2015, Margalef, Pons, Muguerza et al., 2014, Mulek, Hogger, 2015, Takagaki, Nanjo, 2013).

### C-ring cleavage of catechin

The metabolic conversion of monomeric catechins into 3-hydroxyphenyl acetic acid and 3,4-dihydroxyphenyl acetic acid, as observed by Gonthier *et al.* (Gonthier, Cheynier, Donovan et al., 2003), must involve cleavage of the C<sub>3</sub>-C<sub>4</sub> bond and resembles the cleavage of the terminal C-C bond of 2-oxoglutaric acid in  $\alpha$ -ketoglutarate dependent dioxygenases (Silverman, 2002). In catechin, keto-enol tautomerism yields a keto group at position 3 (Figure 4, intermediate **4.1**), which forms a complex with peroxy-iron of the dioxygenase followed by a 5-membered transition state. Subsequently, the A-ring *p*-hydroxy group initiates the C<sub>3</sub>-C<sub>4</sub> cleavage in catechin, thereby producing a quinone methide species, and iron-oxo species, and 3,4-dihydroxyphenyl acetic acid (**4.4**). The A-ring derived quinone methide has not been reported as a metabolite of catechin; this product is expected to undergo further catabolism by reverse Claisen reactions as shown in Figure 3.

### C-C cleavage of dihydrochalcones

An example of a C-C cleavage that is not mediated by dioxygenases is the cleavage of the C<sub>1</sub>'-CO bond in dihydrochalcones by the anaerobic gut bacterium *Eubacterium ramulus*. Blaut and co-workers identified a hydrolase from *E. ramulus* that catalyzes the conversion of phloretin (**5.1**) into 3-(4-hydroxyphenyl)propanoic acid (**5.3**) and phloroglucinol (**5.4**), and named it Phy (Schoefer, Braune, Blaut, 2004). They cloned the gene encoding the enzyme which they biochemically characterized. Its sequence suggested that Phy has similarity to PhIG, a 2,4-diacetylphloroglucinol hydrolase from *Pseudomonas fluorescens* (Bottiglieri, Keel, 2006, He, Huang, Xue et al., 2010, Schnider-Keel, Seematter, Maurhofer et al., 2000). The mechanism of the Phy-catalyzed hydrolytic C-C cleavage can be characterized as a reverse Claisen cleavage reaction facilitated by a 6-membered transition state (**5.2**, Figure 5). Although phloretin and its *O*-glycosides are a well-known dihydrochalcones from apples, phloretin can also be derived from gut microbial conversion from naringenin via

chalconaringenin. In this pathway, the conversion of naringenin into chalconaringenin is mediated by bacterial chalcone isomerase and the conversion of chalconaringenin into phloretin by enoate reductase (Gall, Thomsen, Peters et al., 2014; Herles, Braune, Blaut, 2004; Thomsen, Tuukkanen, Dickerhoff et al., 2015).

## Dehydroxylation of polyphenols

The removal of a *p*-hydroxy group from an aromatic ring is energetically unfavorable and requires an activated precursor. The best described example is the metabolic conversion of 4-hydroxybenzoic acid into benzoic acid by anaerobic bacteria. In this reaction, the carboxyl group is first 'activated' as its coenzyme A thioester by 4-hydroxybenzyl CoA ligase (Carmona, Zamarro, Blazquez et al., 2009; McInerney, Gieg, 2004). Next, the thioester forms the intermediate quinone methide tautomer, which is reduced by a ferredoxin. The resulting semi-hydroquinone sets the stage for the dehydration step to form benzoyl-CoA, which yields benzoic acid upon hydrolysis (Figure 6).

Carboxyl group-driven dehydroxylations of polyphenols are illustrated by the example of the gut microbial conversion of ellagic acid into urolithins. Strawberries, pomegranate juice, and walnuts are good sources of dietary ellagic acid (Gonzalez-Sarrias, Gimenez-Bastida, Garcia-Conesa et al., 2010; Nunez-Sanchez, Garcia-Villalba, Monedero-Saiz et al., 2014; Tomas-Barberan, Garcia-Villalba, Gonzalez-Sarrias et al., 2014; Truchado, Larrosa, Garcia-Conesa et al., 2012), which is formed by C-C coupling of two molecules of gallic acid followed by intramolecular condensation to form the di-lactone. Urolithins are arguably the main urinary biomarkers of nut consumption (Tulipani, Urpi-Sarda, Garcia-Villalba et al., 2012). In the metabolic pathway from ellagic acid to urolithins, one of the two lactone moieties undergoes hydrolysis, and the quinone methide tautomer of the resulting carboxylic acid is reduced, similar to the ferredoxin-mediated reduction of 4-hydroxybenzoic acid shown in Figure 6. The result is a semi-hydroquinone, of which the *p*-hydroxy group leaves as a water molecule following decarboxylation (Figure 7, step iii). Subsequent dehydroxylations can occur, all via reduction of quinone-methide tautomers, to form urolithins C, A, and B (Figure 7).

In the microbial pathway to the urolithins, only the first dehydroxylation is driven by decarboxylation. Subsequent dehydroxylations involve a staged reduction of a quinone, in which keto-enol tautomerism first produces a secondary alcohol and subsequent hydride attack of the quinone drives the dehydration step. Analogous dehydrations are evident in the dehydroxylation of catechin (see Figure 3), leading to the formation of 3-hydroxyphenyl- $\gamma$ -valerolactone. In addition, the pathway described for dehydroxylation of 4-hydroxybenzoic acid would explain the formation of 3-hydroxybenzoic acid from protocatechuic acid derived from Cring cleavage of cyanidin or quercetin (Figures 1 and 2).

## Hydrogenations of enone and keto moieties

### Biotransformation of curcumin into tetrahydrocurcumin

The prototypic dietary polyphenols containing alkene moieties are curcumin and resveratrol. Numerous metabolites of curcumin, a yellow pigment from turmeric, have been identified in



animal and human studies, including hydrogenated (dihydro, tetrahydro, hexahydro, and octahydro metabolites), desmethyl, glucuronide, and sulfate metabolites (Holder, Plummer, Ryan, 1978; Ireson, Jones, Orr et al., 2002). Hassaninasab and co-workers identified an NADPH-dependent reductase in *E.coli* isolated from human feces that is capable of stepwise reduction of curcumin (Hassaninasab, Hashimoto, Tomita-Yokotani et al., 2011) (Figure 8). The enzyme, which they named NADPH-dependent curcumin/dihydrocurcumin reductase or CurA, showed selectivity for curcumin as the substrate and did not further reduce tetrahydrocurcumin to the corresponding secondary alcohols. The corresponding gene, *curA*, was identified as a member of the medium-chain dehydrogenase/reductase superfamily (Hassaninasab, Hashimoto, Tomita-Yokotani et al., 2011).

### Conversion of resveratrol to dihydroresveratrol

Resveratrol, a stilbene found in wine and grapes, has received much attention in the past decade due to its wide spectrum of health claims. A thorough study conducted by Bode *et al.* (Bode, Bunzel, Huch et al., 2013) demonstrated that the main gut microbial metabolites of resveratrol are dihydroresveratrol and the *m*-deoxy metabolites of both resveratrol and dihydroresveratrol (Figure 9). Using a panel of gut microbes, they identified *Slackia equolifaciens* and *Adlercreutzia equolifaciens* as dihydroresveratrol producers.

Upon incubation of resveratrol with fecal samples, the kinetic profiles of resveratrol and its metabolites indicated that both dihydroresveratrol and 3,4'-dihydroxystilbene can serve as intermediates for the formation of lunularin (Figure 9) (Bode, Bunzel, Huch et al., 2013).

### Conversion of daidzein to equol

The main dietary sources of isoflavones are legumes and soy-based foods. Daidzin is one of the most abundantly present isoflavone glycosides in soy and soy products. Isoflavones are among the most potent phytoestrogens found in plants. Isoflavones bind to the estrogen receptor and affect the conformational dynamics in ways distinct from the endogenous ligand estrogen. Therefore isoflavones have been classified as selective estrogen receptor modulators (SERMs) (Brzezinski, Debi, 1999). Metabolism and health promoting properties of dietary soy isoflavones have been recently reviewed by Yuan *et al.* (Yuan, Wang, Liu, 2007) and Rafii (Rafii, 2015).

Enzymatic hydrolysis of the isoflavone glucosides in the small intestine by mammalian  $\beta$ -glucosidases promotes absorption (Bowey, Adlercreutz, Rowland, 2003). The aglycone of daidzin, daidzein, is further metabolized in the liver and transformed into more water-soluble metabolites by *O*-glucuronidation and *O*-sulfation (Legette, Prasain, King et al., 2014). The intestinal microbial transformation of the daidzein entails sequential reduction or hydrogenation reactions and results in the formation of the following metabolites: dihydrodaidzein (DHD, 4',7-dihydroxyisoflavone), tetrahydrodaidzein (THD, 4',7-dihydroxyisoflavan-4-ol), and equol (4',7-dihydroxyisoflavan). An alternative metabolic route produces *O*-desmethylangolensin (*O*-DMA) (Figure 10) (Bowey, Adlercreutz, Rowland, 2003; Heinonen, Hoikkala, Wähälä et al., 2003; Joannou, Kelly, Reeder et al., 1995).

Inter-individual differences in the composition of the gut microbiome and associated biotransformation capacity govern the metabolism of isoflavone and their biological activities (Rafii, 2015; Yuan, Wang, Liu, 2007). The biotransformation of daidzein into equol is dependent on the composition of the gut microbiome. However, the identification of the bacterial species or communities responsible for the conversion of daidzein to equol remains a challenge due to the vast diversity of the microbial communities with an ever-changing composition modifiable by diet, lifestyle, health status and age (van Duynhoven, Vaughan, Jacobs et al., 2011).

Only a few genera of equol-producing bacteria have been isolated and identified from the human intestinal microbiota. Some of the strains host the complete ensemble of enzymes that is capable of facilitating the metabolic conversion of daidzein to equol, whereas other strains are limited in their biotransformation capabilities. Among the genetically best characterized genera of equol-producing bacteria are *Eggerthella* species. For instance, the *Eggerthella* sp. strain YY7918 metabolizes daidzein to equol (Yokoyama, Oshima, Nomura et al., 2011). Maruo *et al.* (Maruo, Sakamoto, Ito et al., 2008) isolated seven strains that were capable of metabolizing daidzein via dihydrodaidzein to equol. Although they found >90% 16S rRNA gene similarity to *Eggerthella* species, there were dissimilarities in cell wall peptidoglycan types and therefore they proposed a new genus and species, *Adlercreutzia equolifaciens* (Maruo, Sakamoto, Ito et al., 2008). A strain with a more restricted enzymatic capability, for instance, is the *Eggerthella* sp. strain Julong 732 which is capable of converting dihydrodaidzein, but not daidzein, into equol (Kim, Kim, Han et al., 2009; Kim, Marsh, Kim et al., 2010).

Other equol-producing bacteria isolated from human fecal material have been identified as taxa of the genus *Slackia*. Examples of genetically and biochemically well-characterized equol-producers are the *Slackia* sp. strain NATTS (Tsuji, Moriyama, Nomoto et al., 2012; Tsuji, Moriyama, Nomoto et al., 2010) and *S. isoflavoniconvertens* (Matthies, Loh, Blaut et al., 2012; Schroder, Matthies, Engst et al., 2013).

Uchiyama and co-workers were the first to isolate an equol-producing lactic acid bacterium from human feces that they identified by 16S rRNA analysis as *Lactococcus* sp. strain 20-92 which belongs to the species *Lactococcus garvieae* (Uchiyama, Ueno, Suzuki, 2013). Subsequently, Shimada and co-workers reported a detailed analysis of the enzyme machinery responsible for the biotransformation of daidzein into equol in *L. garvieae* strain 20-92 (Shimada, Takahashi, Miyazawa et al., 2012; Shimada, Takahashi, Miyazawa et al., 2011; Shimada, Yasuda, Takahashi et al., 2010).

### Chemistry and enzyme systems for daidzein to equol conversion

The biosynthetic pathway of (*S*)-equol is interesting because the transformation begins with the achiral substrate daidzein but all subsequent reaction steps proceed stereospecifically with chiral intermediates. The enzymatic reduction of the <sup>2,3</sup> double bond in daidzein results in the formation of dihydrodaidzein with a chiral center at the C-3 position (Kim, Marsh, Kim et al., 2010). Subsequent reductive transformations result in the formation of (3*R*,4*S*)-tetrahydrodaidzein and (*S*)-equol (Kim, Marsh, Kim et al., 2010). Human intestinal microbiota produce exclusively (*S*)-equol (Setchell, Clerici, Lephart et al., 2005).

Detailed description of the genes and biochemical characterizations of the major daidzein-converting enzymes are available for three equol-forming bacterial strains, i.e., *Slackia* sp. strain NATTS, *Slackia isoflavoniconvertens*, and *Lactococcus* sp. strain 20-92 (Schroder, Matthies, Engst et al., 2013; Shimada, Takahashi, Miyazawa et al., 2012; Shimada, Takahashi, Miyazawa et al., 2011; Shimada, Yasuda, Takahashi et al., 2010; Tsuji, Moriyama, Nomoto et al., 2012). The organization of the gene cluster involved in the biosynthetic transformation of daidzein is similar in all three bacterial strains with the open reading frames oriented in the same direction in the respective genomes (Figure 11). Cloning and functional characterization of the gene products have consistently shown that the biochemical conversion of daidzein into (*S*)-equol involves the following enzymes: Daidzein reductase (DZNR); dihydrodaidzein reductase (DHDR) and tetrahydrodaidzein reductase (THDR). The amino acid sequences of these proteins showed high homology for the three daidzein-to-equol converting bacteria, i.e., *S. isoflavoniconvertens*, *Slackia* sp. strain NATTS, and *Lactococcus* sp. strain 20-92 (Table 2). In addition to the three reductases, Schroder *et al.* and Shimada *et al.* described an auxiliary enzyme, a dihydrodaidzein racemase, which is capable of catalyzing the conversion of (*R*)-dihydrodaidzein to (*S*)-dihydrodaidzein (Schroder, Matthies, Engst et al., 2013; Shimada, Takahashi, Miyazawa et al., 2012).

Bioinformatic analysis of the encoding genes and amino acid sequences of the proteins associated with the daidzein-to-equol conversion allowed the classification of the enzymes based on sequence homology and identification of consensus sequences associated with cofactor binding and active site architectures (Table 3) (Schroder, Matthies, Engst et al., 2013; Tsuji, Moriyama, Nomoto et al., 2012). The first enzyme of the conversion cascade, DZNR showed similarities to the old yellow enzyme (OYE) family (Karplus, Fox, Massey, 1995). Based on consensus sequences for an extended dinucleotide binding motif, a cysteine-rich sequence region that identifies 4Fe-4S cluster binding and a FMN binding motif DZNR was classified as belonging to the NAD(P)H:flavin oxidoreductase family. The sequence of DHDR showed the typical active site tetrad, YX<sub>3</sub>K, for classical short-chain dehydrogenase/reductases (SDRs) and a conserved dinucleotide binding motif (Schroder, Matthies, Engst et al., 2013; Tsuji, Moriyama, Nomoto et al., 2012). Tetrahydrodaidzein reductase (THDR) was classified as a member of the glycyl radical enzyme family based on the RVXG motif and the presence of a dinucleotide binding motif near the N-terminus (Buckel, Golding, 2006; Schroder, Matthies, Engst et al., 2013; Shisler, Broderick, 2014). A radical-based reduction mechanism for the conversion of (3*S*,4*R*)-tetrahydrodaidzein to (*S*)-equol is consistent with the proposed mechanism by Kim *et al.* (Kim, Marsh, Kim et al., 2010), Figure 12).

In addition to the three reductases, Shimada *et al.* described a fourth enzyme encoded in the gene cluster for daidzein-metabolizing enzymes in *Lactococcus* sp. strain 20-92 (Shimada, Takahashi, Miyazawa et al., 2012). Based on sequence homology to bacterial methylmalonyl coenzyme A (methylmalonyl-CoA) epimerases from *Chlorobium* spp. and subsequent functional characterization of the recombinant *Lactococcus* protein, this enzyme was identified as dihydrodaidzein racemase (DDRC). The enzyme is capable of converting each of the dihydrodaidzein enantiomers into the other to yield the racemate. It is conceivable that the enzymatic racemization proceeds via enolization and epimerization (Figure 13). The

respective putative proteins in *Eggerthella* sp. strain YY7918 and *S. isoflavoniconvertens* show high sequence similarities with 99% and 81.5% identity, respectively. Biochemical experiments seem to indicate that DHDR prefers (*S*)-dihydrodaidzein as substrate. Efficient conversion of daidzein to (*S*)-equol was observed using a mixture of the four recombinant *Lactococcus* proteins DZNR, DHDR, THDR, and DDRC (Shimada, Takahashi, Miyazawa et al., 2012).

### Stereospecific transformation of (3*S*,4*R*)-tetrahydrodaidzein to (*S*)-equol

The stereochemistry of the enzymatic conversion of intermediates involved in the biosynthetic route to (*S*)-equol have been studied by Kim *et al.* using partially characterized enzymes from *Eggerthella* sp. strain Julong 732 (Kim, Marsh, Kim et al., 2010). Kim *et al.* used deuterium-labeled tetrahydrodaidzein to conduct mechanistic studies of the stereospecific transformation of (3*S*,4*R*)-tetrahydrodaidzein to (*S*)-equol. Their observations allowed proposing a radical-based mechanism in analogy to ribonucleotide reductases. In this model (Figure 12), biotransformation of (3*S*,4*R*)-tetrahydrodaidzein is initiated by abstraction of hydrogen from the C-3 position triggered by an enzyme-based radical, X<sup>•</sup> thereby yielding a relatively stable benzylic radical. It is conceivable that the radical at C-3 induces loss of the hydroxyl group at position 4 under generation of a radical cation. Subsequent reduction of this intermediate by a hydride donor can then occur at C-4 with retention of the stereochemistry in accord with the observed deuterium labeling pattern. Finally, the biotransformation is completed by the addition of hydrogen to C-3 under preservation of the correct stereochemistry and formation of (3*S*)-equol. The authors note that tetrahydrodaidzein reductase (THDR) activity is only observed under strictly anaerobic conditions which would be consistent with that THDR is possibly a radical enzyme belonging to the glycyl radical enzyme family (Buckel, Golding, 2006; Schroder, Matthies, Engst et al., 2013; Shisler, Broderick, 2014).

### Conversion of daidzein to *O*-desmethylangolensin

The other major metabolite of daidzein is *O*-desmethylangolensin. Formation of *O*-desmethylangolensin involves cleavage of the C-ring, and so far only a few bacterial strains have been described that have the genetic make-up to catalyze this biotransformation which include *Eubacterium ramulus* (Schoefer, Mohan, Braune et al., 2002), *E. ramulus* strain Julong 601 (Wang, Kim, Lee et al., 2004) and *Clostridium* sp. strain HGH 136 (Hur, Beger, Heinze et al., 2002).

Early studies of human urinary metabolites suggested that the metabolic transformation of daidzein to *O*-desmethylangolensin proceeds via 2-dehydro-*O*-desmethylangolensin (Figure 14) (Bowey, Adlercreutz, Rowland, 2003; Heinonen, Hoikkala, Wähälä et al., 2003; Joannou, Kelly, Reeder et al., 1995). However, the enzymes responsible for the C-ring fission and reduction have not been characterized yet.

*O*-Desmethylangolensin has a chiral center which poses the question which of the two enantiomers is predominately produced *in vivo*. Gardana *et al.* showed that the metabolism of daidzein in anaerobic batch cultures inoculated with mixed fecal bacteria produces *R*(-)-*O*-desmethylangolensin as the predominant product with an enantiomeric excess (EE) of

91% (Gardana, Canzi, Simonetti, 2014). Combined chiroptical studies with time-dependent density functional theory calculation supported a stereospecific biosynthetic route that proceeds predominantly via (–)-(S)-dihydrodaidzein to yield the urinary metabolite (–)-(R)-O-desmethylangolensin (Kim, Han, 2014).

## Conclusion and perspective

The systemic health benefits of dietary polyphenols cannot be satisfactorily explained by their oral bioavailability and host metabolism. Knowledge of the composition of gut microbiota and their functional capacity, obtained by metabolomics analysis in conjunction with bioinformatics analysis of microbial genes, may allow the characterization of ‘enterotypes’ or ‘nutritional phenotypes’, thereby providing a link between bioactive metabolites and the health benefits of dietary polyphenols (van Duynhoven, Vaughan, Jacobs et al., 2011). The empty entries in Table 1 exemplify that much work on the enzymology and identification of genes coding for metabolic enzymes remains to be completed before ‘enterotypes’ can be predicted on the basis of gene sequencing (Knights, Ward, McKinlay et al., 2014).

## References

- Amin HP, Czank C, Raheem S, et al. Anthocyanins and their physiologically relevant metabolites alter the expression of IL-6 and VCAM-1 in CD40L and oxidized LDL challenged vascular endothelial cells. *Mol Nutr Food Res*. 2015; 59:1095–1106. [PubMed: 25787755]
- Appeldoorn MM, Vincken JP, Aura AM, et al. Procyanidin dimers are metabolized by human microbiota with 2-(3,4-dihydroxyphenyl)acetic acid and 5-(3,4-dihydroxyphenyl)-gamma-valerolactone as the major metabolites. *J Agric Food Chem*. 2009; 57:1084–1092. [PubMed: 19191673]
- Aura AM, Martin-Lopez P, O’Leary KA, et al. In vitro metabolism of anthocyanins by human gut microflora. *Eur J Nutr*. 2005; 44:133–142. [PubMed: 15309431]
- Barroso E, Sanchez-Patan F, Martin-Alvarez PJ, et al. *Lactobacillus plantarum* IFPL935 favors the initial metabolism of red wine polyphenols when added to a colonic microbiota. *J Agric Food Chem*. 2013; 61:10163–10172. [PubMed: 24073689]
- Bitsch I, Janssen M, Netzel M, et al. Bioavailability of anthocyanidin-3-glycosides following consumption of elderberry extract and blackcurrant juice. *Int J Clin Pharmacol Ther*. 2004; 42:293–300. [PubMed: 15176653]
- Bode LM, Bunzel D, Huch M, et al. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. *Am J Clin Nutr*. 2013; 97:295–309. [PubMed: 23283496]
- Bottiglieri M, Keel C. Characterization of PhIG, a hydrolase that specifically degrades the antifungal compound 2,4-diacetylphloroglucinol in the biocontrol agent *Pseudomonas fluorescens* CHA0. *Appl Environ Microbiol*. 2006; 72:418–427. [PubMed: 16391073]
- Bowater L, Fairhurst SA, Just VJ, et al. *Bacillus subtilis* YxaG is a novel Fe-containing quercetin 2,3-dioxygenase. *FEBS Letters*. 2004; 557:45–48. [PubMed: 14741339]
- Bowey E, Adlercreutz H, Rowland I. Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats. *Food Chem Toxicol*. 2003; 41:631–636. [PubMed: 12659715]
- Brzezinski A, Debi A. Phytoestrogens: the “natural” selective estrogen receptor modulators? *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 1999; 85:47–51. [PubMed: 10428321]
- Bub A, Watzl B, Heeb D, et al. Malvidin-3-glucoside bioavailability in humans after ingestion of red wine, dealcoholized red wine and red grape juice. *Eur J Nutr*. 2001; 40:113–120. [PubMed: 11697443]

- Buckel W, Golding BT. Radical enzymes in anaerobes. *Annu Rev Microbiol.* 2006; 60:27–49. [PubMed: 16704345]
- Cao G, Prior RL. Comparison of different analytical methods for assessing total antioxidant capacity of human serum. *Clin Chem.* 1998; 44:1309–1315. [PubMed: 9625058]
- Carmona M, Zamarro MT, Blazquez B, et al. Anaerobic Catabolism of Aromatic Compounds: a Genetic and Genomic View. *Microbiology and Molecular Biology Reviews.* 2009; 73:71. [PubMed: 19258534]
- Chadwick RW, George SE, Claxton LD. Role of the gastrointestinal mucosa and microflora in the bioactivation of dietary and environmental mutagens or carcinogens. *Drug Metab Rev.* 1992; 24:425–492. [PubMed: 1289035]
- Czank C, Cassidy A, Zhang Q, et al. Human metabolism and elimination of the anthocyanin, cyanidin-3-glucoside: a (13)C-tracer study. *Am J Clin Nutr.* 2013; 97:995–1003. [PubMed: 23604435]
- Donovan JL, Manach C, Rios L, et al. Procyanidins are not bioavailable in rats fed a single meal containing a grapeseed extract or the procyanidin dimer B3. *Br J Nutr.* 2002; 87:299–306. [PubMed: 12064339]
- Eggler AL, Gay KA, Mesecar AD. Molecular mechanisms of natural products in chemoprevention: Induction of cytoprotective enzymes by Nrf2. *Molecular Nutrition & Food Research.* 2008; 52:S84–S94. [PubMed: 18435489]
- Eggler, Aimee L, Small E, Hannink M, et al. Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1. 2009
- Felgines C, Talavera S, Gonthier MP, et al. Strawberry anthocyanins are recovered in urine as glucuro- and sulfoconjugates in humans. *J Nutr.* 2003; 133:1296–1301. [PubMed: 12730413]
- Fetzner S. Ring-Cleaving Dioxygenases with a Cupin Fold. *Applied and Environmental Microbiology.* 2012; 78:2505–2514. [PubMed: 22287012]
- Gall M, Thomsen M, Peters C, et al. Enzymatic conversion of flavonoids using bacterial chalcone isomerase and enoate reductase. *Angew Chem Int Ed Engl.* 2014; 53:1439–1442. [PubMed: 24459060]
- Garcia-Villalba R, Beltran D, Espin JC, et al. Time course production of urolithins from ellagic acid by human gut microbiota. *J Agric Food Chem.* 2013; 61:8797–8806. [PubMed: 23984796]
- Gardana C, Canzi E, Simonetti P. R(-)-O-desmethylangolensin is the main enantiomeric form of daidzein metabolite produced by human in vitro and in vivo. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2014; 953–954:30–37.
- Gonthier MP, Cheynier V, Donovan JL, et al. Microbial aromatic acid metabolites formed in the gut account for a major fraction of the polyphenols excreted in urine of rats fed red wine polyphenols. *J Nutr.* 2003; 133:461–467. [PubMed: 12566484]
- Gonzalez-Sarrias A, Gimenez-Bastida JA, Garcia-Conesa MT, et al. Occurrence of urolithins, gut microbiota ellagic acid metabolites and proliferation markers expression response in the human prostate gland upon consumption of walnuts and pomegranate juice. *Mol Nutr Food Res.* 2010; 54:311–322. [PubMed: 19885850]
- Goodrich KM, Neilson AP. Simultaneous UPLC-MS/MS analysis of native catechins and procyanidins and their microbial metabolites in intestinal contents and tissues of male Wistar Furth inbred rats. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2014; 958:63–74.
- Gray NE, Sampath H, Zweig JA, et al. Centella asiatica Attenuates Amyloid-beta-Induced Oxidative Stress and Mitochondrial Dysfunction. *J Alzheimers Dis.* 2015; 45:933–946. [PubMed: 25633675]
- Gu L, Kelm MA, Hammerstone JF, et al. Concentrations of proanthocyanidins in common foods and estimations of normal consumption. *J Nutr.* 2004; 134:613–617. [PubMed: 14988456]
- Hanske L, Loh G, Sczesny S, et al. The bioavailability of apigenin-7-glucoside is influenced by human intestinal microbiota in rats. *J Nutr.* 2009; 139:1095–1102. [PubMed: 19403720]
- Hanske L, Loh G, Sczesny S, et al. Recovery and metabolism of xanthohumol in germ-free and human microbiota-associated rats. *Mol Nutr Food Res.* 2010; 54:1405–1413. [PubMed: 20397197]
- Harini R, Pugalendi KV. Antihyperglycemic effect of protocatechuic acid on streptozotocin-diabetic rats. *J Basic Clin Physiol Pharmacol.* 2010; 21:79–91. [PubMed: 20506690]

- Hassaninasab A, Hashimoto Y, Tomita-Yokotani K, et al. Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. *Proc Natl Acad Sci U S A*. 2011; 108:6615–6620. [PubMed: 21467222]
- He YX, Huang L, Xue Y, et al. Crystal structure and computational analyses provide insights into the catalytic mechanism of 2,4-diacetylphloroglucinol hydrolase PhlG from *Pseudomonas fluorescens*. *J Biol Chem*. 2010; 285:4603–4611. [PubMed: 20018877]
- Hein EM, Rose K, van't Slot G, et al. Deconjugation and degradation of flavonol glycosides by pig cecal microbiota characterized by Fluorescence in situ hybridization (FISH). *J Agric Food Chem*. 2008; 56:2281–2290. [PubMed: 18303842]
- Heinken A, Thiele I. Anoxic Conditions Promote Species-Specific Mutualism between Gut Microbes In Silico. *Appl Environ Microbiol*. 2015; 81:4049–4061. [PubMed: 25841013]
- Heinonen S-M, Hoikkala A, Wähälä K, et al. Metabolism of the soy isoflavones daidzein, genistein and glycitein in human subjects.: Identification of new metabolites having an intact isoflavonoid skeleton. *The Journal of Steroid Biochemistry and Molecular Biology*. 2003; 87:285–299. [PubMed: 14698210]
- Herles C, Braune A, Blaut M. First bacterial chalcone isomerase isolated from *Eubacterium ramulus*. *Arch Microbiol*. 2004; 181:428–434. [PubMed: 15127184]
- Hirooka K, Fujita Y. Excess Production of *Bacillus subtilis* Quercetin 2,3-Dioxygenase Affects Cell Viability in the Presence of Quercetin. *Bioscience Biotechnology and Biochemistry*. 2010; 74:1030–1038.
- Hoffmann T, Troup B, Szabo A, et al. The anaerobic life of *Bacillus subtilis*: cloning of the genes encoding the respiratory nitrate reductase system. *FEMS Microbiol Lett*. 1995; 131:219–225. [PubMed: 7557333]
- Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. *Xenobiotica*. 1978; 8:761–768. [PubMed: 726520]
- Hong HA, Khaneja R, Tam NM, et al. *Bacillus subtilis* isolated from the human gastrointestinal tract. *Res Microbiol*. 2009; 160:134–143. [PubMed: 19068230]
- Huang D, Ou B, Prior RL. The chemistry behind antioxidant capacity assays. *J Agric Food Chem*. 2005; 53:1841–1856. [PubMed: 15769103]
- Hur HG, Beger RD, Heinze TM, et al. Isolation of an anaerobic intestinal bacterium capable of cleaving the C-ring of the isoflavonoid daidzein. *Arch Microbiol*. 2002; 178:8–12. [PubMed: 12070764]
- Ichiyanagi T, Shida Y, Rahman MM, et al. Effect on both aglycone and sugar moiety towards Phase II metabolism of anthocyanins. *Food Chem*. 2008; 110:493–500. [PubMed: 26049244]
- Ireson CR, Jones DJ, Orr S, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. *Cancer Epidemiol Biomarkers Prev*. 2002; 11:105–111. [PubMed: 11815407]
- Jimenez-Giron A, Ibanez C, Cifuentes A, et al. Faecal metabolomic fingerprint after moderate consumption of red wine by healthy subjects. *J Proteome Res*. 2015; 14:897–905. [PubMed: 25496753]
- Joannou GE, Kelly GE, Reeder AY, et al. A urinary profile study of dietary phytoestrogens. The identification and mode of metabolism of new isoflavonoids. *The Journal of Steroid Biochemistry and Molecular Biology*. 1995; 54:167–184. [PubMed: 7662591]
- Kakkar S, Bais S. A review on protocatechuic Acid and its pharmacological potential. *ISRN Pharmacol*. 2014; 2014:952943. [PubMed: 25006494]
- Kang S, Joo C, Kim SM, et al. Oxidation of benzoins to benzoic acids using sodium hydride under oxygen atmosphere. *Tetrahedron Letters*. 2011; 52:502–504.
- Karplus PA, Fox KM, Massey V. Flavoprotein structure and mechanism. 8. Structure-function relations for old yellow enzyme. *FASEB J*. 1995; 9:1518–1526. [PubMed: 8529830]
- Kavanagh KL, Jornvall H, Persson B, et al. Medium- and short-chain dehydrogenase/reductase gene and protein families : the SDR superfamily: functional and structural diversity within a family of metabolic and regulatory enzymes. *Cell Mol Life Sci*. 2008; 65:3895–3906. [PubMed: 19011750]
- Kay CD, Mazza G, Holub BJ, et al. Anthocyanin metabolites in human urine and serum. *Br J Nutr*. 2004; 91:933–942. [PubMed: 15228048]


- Kim M, Han J. Chiroptical Study and Absolute Configuration of (–)-O-DMA Produced From Daidzein Metabolism. *Chirality*. 2014; 26:434–437. [PubMed: 24519947]
- Kim M, Kim SI, Han J, et al. Stereospecific biotransformation of dihydrodaidzein into (3S)-equol by the human intestinal bacterium *Eggerthella* strain Julong 732. *Appl Environ Microbiol*. 2009; 75:3062–3068. [PubMed: 19304836]
- Kim M, Marsh EN, Kim SU, et al. Conversion of (3S,4R)-tetrahydrodaidzein to (3S)-equol by THD reductase: proposed mechanism involving a radical intermediate. *Biochemistry*. 2010; 49:5582–5587. [PubMed: 20515029]
- Knights D, Ward TL, McKinlay CE, et al. Rethinking “enterotypes”. *Cell Host Microbe*. 2014; 16:433–437. [PubMed: 25299329]
- Kumar H, Kim I-S, More SV, et al. Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases. *Natural Product Reports*. 2014; 31:109–139. [PubMed: 24292194]
- Lee-Hilz YY, Boerboom AM, Westphal AH, et al. Pro-oxidant activity of flavonoids induces EpRE-mediated gene expression. *Chem Res Toxicol*. 2006; 19:1499–1505. [PubMed: 17112238]
- Lee I-S, Lim J, Gal J, et al. Anti-inflammatory activity of xanthohumol involves heme oxygenase-1 induction via NRF2-ARE signaling in microglial BV2 cells. *Neurochemistry International*. 2011; 58:153–160. [PubMed: 21093515]
- Legette L, Ma L, Reed RL, et al. Pharmacokinetics of xanthohumol and metabolites in rats after oral and intravenous administration. *Mol Nutr Food Res*. 2012; 56:466–474. [PubMed: 22147307]
- Legette LL, Luna AY, Reed RL, et al. Xanthohumol lowers body weight and fasting plasma glucose in obese male Zucker fa/fa rats. *Phytochemistry*. 2013; 91:236–241. [PubMed: 22640929]
- Legette LL, Prasain J, King J, et al. Pharmacokinetics of equol, a soy isoflavone metabolite, changes with the form of equol (dietary versus intestinal production) in ovariectomized rats. *J Agric Food Chem*. 2014; 62:1294–1300. [PubMed: 24446705]
- Lin HH, Chen JH, Chou FP, et al. Protocatechuic acid inhibits cancer cell metastasis involving the down-regulation of Ras/Akt/NF-kappaB pathway and MMP-2 production by targeting RhoB activation. *Br J Pharmacol*. 2011; 162:237–254. [PubMed: 20840540]
- Ma Z-C, Hong Q, Wang Y-G, et al. Ferulic Acid Protects Human Umbilical Vein Endothelial Cells from Radiation Induced Oxidative Stress by Phosphatidylinositol 3-Kinase and Extracellular Signal-Regulated Kinase Pathways. *Biological and Pharmaceutical Bulletin*. 2010; 33:29–34. [PubMed: 20045931]
- Margalef M, Pons Z, Mugerza B, et al. A rapid method to determine colonic microbial metabolites derived from grape flavanols in rat plasma by liquid chromatography-tandem mass spectrometry. *J Agric Food Chem*. 2014; 62:7698–7706. [PubMed: 25069016]
- Maruo T, Sakamoto M, Ito C, et al. *Adlercreutzia equolifaciens* gen. nov., sp. nov., an equol-producing bacterium isolated from human faeces, and emended description of the genus *Eggerthella*. *Int J Syst Evol Microbiol*. 2008; 58:1221–1227. [PubMed: 18450717]
- Masella R, Santangelo C, D’Archivio M, et al. Protocatechuic acid and human disease prevention: biological activities and molecular mechanisms. *Curr Med Chem*. 2012; 19:2901–2917. [PubMed: 22519395]
- Matthies A, Loh G, Blaut M, et al. Daidzein and genistein are converted to equol and 5-hydroxy-equol by human intestinal *Slackia isoflavoniconvertens* in gnotobiotic rats. *J Nutr*. 2012; 142:40–46. [PubMed: 22113864]
- McInerney, MJ.; Gieg, LM. An overview of anaerobic metabolism. In: Nakano, MM.; Zuber, P., editors. *Strict and facultative anaerobes: Medical and environmental aspects*. Horizon Bioscience; Norfolk, England: 2004. p. 27-66.
- Mertens-Talcott SU, Rios J, Jilma-Stohlawetz P, et al. Pharmacokinetics of anthocyanins and antioxidant effects after the consumption of anthocyanin-rich acai juice and pulp (*Euterpe oleracea* Mart.) in human healthy volunteers. *J Agric Food Chem*. 2008; 56:7796–7802. [PubMed: 18693743]
- Milligan SR, Kalita JC, Pocock V, et al. The endocrine activities of 8-prenylnaringenin and related hop (*Humulus lupulus* L.) flavonoids. *J Clin Endocrinol Metab*. 2000; 85:4912–4915. [PubMed: 11134162]




- Mulek M, Hogger P. Highly sensitive analysis of polyphenols and their metabolites in human blood cells using dispersive SPE extraction and LC-MS/MS. *Anal Bioanal Chem.* 2015; 407:1885–1899. [PubMed: 25579463]
- Nunez-Sanchez MA, Garcia-Villalba R, Monedero-Saiz T, et al. Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients. *Mol Nutr Food Res.* 2014; 58:1199–1211. [PubMed: 24532260]
- Oppermann U, Filling C, Hult M, et al. Short-chain dehydrogenases/reductases (SDR): the 2002 update. *Chem Biol Interact.* 2003; 143–144:247–253.
- Peiffer DS, Zimmerman NP, Wang LS, et al. Chemoprevention of esophageal cancer with black raspberries, their component anthocyanins, and a major anthocyanin metabolite, protocatechuic acid. *Cancer Prev Res (Phila).* 2014; 7:574–584. [PubMed: 24667581]
- Peng X, Zhang Z, Zhang N, et al. In vitro catabolism of quercetin by human fecal bacteria and the antioxidant capacity of its catabolites. *Food Nutr Res.* 2014:58.
- Pompella A, Sies H, Wacker R, et al. The use of total antioxidant capacity as surrogate marker for food quality and its effect on health is to be discouraged. *Nutrition.* 2014; 30:791–793. [PubMed: 24984994]
- Possemiers S, Bolca S, Grootaert C, et al. The prenylflavonoid isoxanthohumol from hops (*Humulus lupulus* L.) is activated into the potent phytoestrogen 8-prenylnaringenin in vitro and in the human intestine. *J Nutr.* 2006; 136:1862–1867. [PubMed: 16772450]
- Possemiers S, Heyerick A, Robbens V, et al. Activation of proestrogens from hops (*Humulus lupulus* L.) by intestinal microbiota; conversion of isoxanthohumol into 8-prenylnaringenin. *J Agric Food Chem.* 2005; 53:6281–6288. [PubMed: 16076107]
- Rafii F. The role of colonic bacteria in the metabolism of the natural isoflavone daidzin to equol. *Metabolites.* 2015; 5:56–73. [PubMed: 25594250]
- Rasmussen SE, Frederiksen H, Struntze Krogholm K, et al. Dietary proanthocyanidins: occurrence, dietary intake, bioavailability, and protection against cardiovascular disease. *Mol Nutr Food Res.* 2005; 49:159–174. [PubMed: 15635686]
- Rechner AR, Smith MA, Kuhnle G, et al. Colonic metabolism of dietary polyphenols: influence of structure on microbial fermentation products. *Free Radic Biol Med.* 2004; 36:212–225. [PubMed: 14744633]
- Schaab MR, Barney BM, Francisco WA. Kinetic and spectroscopic studies on the quercetin 2,3-dioxygenase from *Bacillus subtilis*. *Biochemistry.* 2006; 45:1009–1016. [PubMed: 16411777]
- Schneider H, Simmering R, Hartmann L, et al. Degradation of quercetin-3-glucoside in gnotobiotic rats associated with human intestinal bacteria. *J Appl Microbiol.* 2000; 89:1027–1037. [PubMed: 11123476]
- Schnider-Keel U, Seematter A, Maurhofer M, et al. Autoinduction of 2,4-diacetylphloroglucinol biosynthesis in the biocontrol agent *Pseudomonas fluorescens* CHA0 and repression by the bacterial metabolites salicylate and pyoluteorin. *J Bacteriol.* 2000; 182:1215–1225. [PubMed: 10671440]
- Schoefer L, Braune A, Blaut M. Cloning and expression of a phloretin hydrolase gene from *Eubacterium ramulus* and characterization of the recombinant enzyme. *Appl Environ Microbiol.* 2004; 70:6131–6137. [PubMed: 15466559]
- Schoefer L, Mohan R, Braune A, et al. Anaerobic C-ring cleavage of genistein and daidzein by *Eubacterium ramulus*. *FEMS Microbiol Lett.* 2002; 208:197–202. [PubMed: 11959436]
- Schroder C, Matthies A, Engst W, et al. Identification and expression of genes involved in the conversion of daidzein and genistein by the equol-forming bacterium *Slackia isoflavoniconvertens*. *Appl Environ Microbiol.* 2013; 79:3494–3502. [PubMed: 23542626]
- Selma MV, Beltran D, Garcia-Villalba R, et al. Description of urolithin production capacity from ellagic acid of two human intestinal *Gordonibacter* species. *Food & Function.* 2014; 5:1779–1784. [PubMed: 24909569]
- Selma MV, Tomas-Barberan FA, Beltran D, et al. *Gordonibacter urolithinifaciens* sp. nov., a urolithin-producing bacterium isolated from the human gut. *Int J Syst Evol Microbiol.* 2014; 64:2346–2352. [PubMed: 24744017]

- Serra A, Macia A, Romero MP, et al. Metabolic pathways of the colonic metabolism of flavonoids (flavonols, flavones and flavanones) and phenolic acids. *Food Chem.* 2012; 130:383–393.
- Setchell KD, Clerici C, Lephart ED, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. *Am J Clin Nutr.* 2005; 81:1072–1079. [PubMed: 15883431]
- Shimada Y, Takahashi M, Miyazawa N, et al. Identification of a novel dihydrodaidzein racemase essential for biosynthesis of equol from daidzein in *Lactococcus* sp. strain 20–92. *Appl Environ Microbiol.* 2012; 78:4902–4907. [PubMed: 22582059]
- Shimada Y, Takahashi M, Miyazawa N, et al. Identification of two novel reductases involved in equol biosynthesis in *Lactococcus* strain 20–92. *J Mol Microbiol Biotechnol.* 2011; 21:160–172. [PubMed: 22286043]
- Shimada Y, Yasuda S, Takahashi M, et al. Cloning and expression of a novel NADP(H)-dependent daidzein reductase, an enzyme involved in the metabolism of daidzein, from equol-producing *Lactococcus* strain 20–92. *Appl Environ Microbiol.* 2010; 76:5892–5901. [PubMed: 20639368]
- Shisler KA, Broderick JB. Glycyl radical activating enzymes: Structure, mechanism, and substrate interactions. *Archives of Biochemistry and Biophysics.* 2014; 546:64–71. [PubMed: 24486374]
- Silverman, RB. The organic chemistry of enzyme-catalyzed reactions. Academic Press; London: 2002.
- Spencer JP, Chaudry F, Pannala AS, et al. Decomposition of cocoa procyanidins in the gastric milieu. *Biochem Biophys Res Commun.* 2000; 272:236–241. [PubMed: 10872833]
- Steiner RA, Kalk KH, Dijkstra BW. Anaerobic enzyme substrate structures provide insight into the reaction mechanism of the copper-dependent quercetin 2,3-dioxygenase. *Proceedings of the National Academy of Sciences.* 2002; 99:16625–16630.
- Sun YJ, Huang QQ, Li P, et al. Catalytic dioxygenation of flavonol by M-complexes (M = Mn, Fe, Co, Ni, Cu and Zn) - mimicking the M-substituted quercetin 2,3-dioxygenase. *Dalton Trans.* 2015
- Takagaki A, Nanjo F. Catabolism of (+)-catechin and (–)-epicatechin by rat intestinal microbiota. *J Agric Food Chem.* 2013; 61:4927–4935. [PubMed: 23621128]
- Taylor CT, Colgan SP. Hypoxia and gastrointestinal disease. *J Mol Med (Berl).* 2007; 85:1295–1300. [PubMed: 18026919]
- Thomsen M, Tuukkanen A, Dickerhoff J, et al. Structure and catalytic mechanism of the evolutionarily unique bacterial chalcone isomerase. *Acta Crystallogr D Biol Crystallogr.* 2015; 71:907–917. [PubMed: 25849401]
- Toh H, Oshima K, Suzuki T, et al. Complete Genome Sequence of the Equol-Producing Bacterium *Adlercreutzia equolifaciens* DSM 19450T. *Genome Announc.* 2013:1.
- Tomas-Barberan FA, Garcia-Villalba R, Gonzalez-Sarrias A, et al. Ellagic acid metabolism by human gut microbiota: consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status. *J Agric Food Chem.* 2014; 62:6535–6538. [PubMed: 24976365]
- Truchado P, Larrosa M, Garcia-Conesa MT, et al. Strawberry processing does not affect the production and urinary excretion of urolithins, ellagic acid metabolites, in humans. *J Agric Food Chem.* 2012; 60:5749–5754. [PubMed: 22126674]
- Tsao SM, Hsia TC, Yin MC. Protocatechuic acid inhibits lung cancer cells by modulating FAK, MAPK, and NF-kappaB pathways. *Nutr Cancer.* 2014; 66:1331–1341. [PubMed: 25356681]
- Tsuji H, Moriyama K, Nomoto K, et al. Identification of an enzyme system for daidzein-to-equol conversion in *Slackia* sp. strain NATTS. *Appl Environ Microbiol.* 2012; 78:1228–1236. [PubMed: 22179235]
- Tsuji H, Moriyama K, Nomoto K, et al. Isolation and characterization of the equol-producing bacterium *Slackia* sp. strain NATTS. *Arch Microbiol.* 2010; 192:279–287. [PubMed: 20237913]
- Tulipani S, Urpi-Sarda M, Garcia-Villalba R, et al. Urolithins are the main urinary microbial-derived phenolic metabolites discriminating a moderate consumption of nuts in free-living subjects with diagnosed metabolic syndrome. *J Agric Food Chem.* 2012; 60:8930–8940. [PubMed: 22631214]
- Turnbaugh PJ, Ridaura VK, Faith JJ, et al. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. *Sci Transl Med.* 2009; 1:6ra14.
- Uchiyama S, Ueno T, Suzuki T. Equol-producing lactic acid bacteria-containing composition. 2013 PCT/JP2004/009484.

- Ulbrich K, Reichardt N, Braune A, et al. The microbial degradation of onion flavonol glucosides and their roasting products by the human gut bacteria *Eubacterium ramulus* and *Flavonifractor plautii*. *Food Research International*. 2015; 67:349–355.
- van Duynhoven J, Vaughan EE, Jacobs DM, et al. Metabolic fate of polyphenols in the human superorganism. *Proc Natl Acad Sci U S A*. 2011; 108(Suppl 1):4531–4538. [PubMed: 20615997]
- Vari R, D'Archivio M, Filesi C, et al. Protocatechuic acid induces antioxidant/detoxifying enzyme expression through JNK-mediated Nrf2 activation in murine macrophages. *The Journal of Nutritional Biochemistry*. 2011; 22:409–417. [PubMed: 20621462]
- Wang D, Xia M, Yan X, et al. Gut microbiota metabolism of anthocyanin promotes reverse cholesterol transport in mice via repressing miRNA-10b. *Circ Res*. 2012; 111:967–981. [PubMed: 22821931]
- Wang LS, Stoner GD. Anthocyanins and their role in cancer prevention. *Cancer Lett*. 2008; 269:281–290. [PubMed: 18571839]
- Wang XL, Kim KT, Lee JH, et al. C-ring cleavage of isoflavones daidzein and genistein by a newly-isolated human intestinal bacterium *Eubacterium ramulus* Julong 601. *Journal of Microbiology and Biotechnology*. 2004; 14:766–771.
- Williamson G, Clifford MN. Colonic metabolites of berry polyphenols: the missing link to biological activity? *Br J Nutr*. 2010; 104(Suppl 3):S48–66. [PubMed: 20955650]
- Woodward GM, Needs PW, Kay CD. Anthocyanin-derived phenolic acids form glucuronides following simulated gastrointestinal digestion and microsomal glucuronidation. *Mol Nutr Food Res*. 2011; 55:378–386. [PubMed: 21370450]
- Xu J, Gordon JI. Honor thy symbionts. *Proc Natl Acad Sci U S A*. 2003; 100:10452–10459. [PubMed: 12923294]
- Yin MC, Lin CC, Wu HC, et al. Apoptotic effects of protocatechuic acid in human breast, lung, liver, cervix, and prostate cancer cells: potential mechanisms of action. *J Agric Food Chem*. 2009; 57:6468–6473. [PubMed: 19601677]
- Yokoyama S, Oshima K, Nomura I, et al. Complete genomic sequence of the equol-producing bacterium *Eggerthella* sp. strain YY7918, isolated from adult human intestine. *J Bacteriol*. 2011; 193:5570–5571. [PubMed: 21914883]
- Yuan JP, Wang JH, Liu X. Metabolism of dietary soy isoflavones to equol by human intestinal microflora--implications for health. *Mol Nutr Food Res*. 2007; 51:765–781. [PubMed: 17579894]



**Figure 1.** Proposed mechanism for the conversion of cyanidin into protocatechuic acid (**1.6**) and 2-(2,4,6-trihydroxyphenyl)acetic acid (**1.7**). Steps: i) hydrolytic attack of the flavylum carbon at position 2, ii) conversion of the hemi-ketal into the keto form followed by keto-enol tautomerism of the neighboring enol yields an  $\alpha$ -diketo species, iii) microbial enzyme-mediated nucleophilic attack of one of the keto carbons by a peroxy anion species, iv) insertion of the alkoxy oxygen results in an acyl anhydride, v) hydrolysis of anhydride releases two phenolic acids.



**Figure 2.**

a) A mechanism for quercetinase-mediated conversion of quercetin (**2.1**) into 2-protocatechuoylphloroglucinolcarboxylic acid (**2.5**) adapted from (Schaab, Barney, Francisco, 2006). Decarboxylation of 1,3,5-trihydroxybenzoic acid (**2.7**) into phloroglucinol (**2.8**) is not mediated by quercetinase. b) The co-crystal structure of *Aspergillus japonicus* quercetinase 2,3 dioxygenase complexed with the natural substrate quercetin under anaerobic condition is available (pdb 1H11). The X-ray structure shows that the flavonol


coordinates to the copper ion through the C-ring OH group at position 3 (Steiner, Kalk, Dijkstra, 2002).

Author Manuscript


Author Manuscript

Author Manuscript

Author Manuscript




**Figure 3.** Gut microbial conversion of (epi)catechin (**3.1**) into 3-hydroxyphenyl- $\gamma$ -valerolactone (**3.13**) by reverse Claisen-driven degradation of the A-ring (steps iv–viii). D = hydride donor, B = basic amino acid residue.




**Figure 4.** Proposed mechanism for gut microbial conversion of (epi)catechin into 2-(3,4-dihydroxyphenyl)acetic acid (**4.4**). Iron is linked to a dioxygenase via one or more amino acids, indicated as L<sub>n</sub>.






**Figure 5.** Reverse Claisen mechanism for the conversion of phloretin (5.1) into 3-(4-hydroxyphenyl)propanoic acid (5.3) and phloroglucinol (5.4).




**Figure 6.** Mechanism for the dehydroxylation of 4-hydroxybenzoic acid according to (Carmona, Zamorro, Blazquez et al., 2009; McInerney, Gieg, 2004).




**Figure 7.**


Gut microbial conversion of ellagic acid into urolithins A, B, and C. In this metabolic pathway, dehydration reactions (ii, v, x) are driven by decarboxylation (ii) and reduction reactions (vii, ix). Other steps: hydrolysis (i) and keto-enol tautomerism (i, iv, vi, viii). D = hydride donor, B = basic amino acid residue.




**Figure 8.** Stepwise reduction of curcumin by the *E. coli* enzyme, CurA (Hassaninasab, Hashimoto, Tomita-Yokotani et al., 2011).



**Figure 9.** Gut microbial metabolism of resveratrol (Bode, Bunzel, Huch et al., 2013).




**Figure 10.** Gut microbial biotransformation of daidzein into the phytoestrogens equol and *O*-desmethylangolensin (*O*-DMA).





**Figure 11.**

Gene organization maps of the gene cluster encoding enzymes involved in the metabolic conversion of daidzein to *S*-equol in three equol-producing bacterial strains: a, *S. isoflavoniconvertens* (Schroder, Matthies, Engst et al., 2013), b, *Slackia* sp. strain NATTS (Tsuji, Moriyama, Nomoto et al., 2012), and c, *Lactococcus* strain 20-92 (Shimada, Takahashi, Miyazawa et al., 2012, Shimada, Takahashi, Miyazawa et al., 2011).


**Figure 12.**

a) Stereospecific conversion of (3*S*,4*R*)-tetrahydrodaidzein (THD) to (*S*)-equol and b) the proposed mechanistic pathway of (3*S*,4*R*)-THD to (*S*)-equol catalyzed by tetrahydrodaidzein reductase (THDR) according to Kim et al. 2010 (Kim, Marsh, Kim et al., 2010).





**Figure 13.**  
Racemization of dihydrodaidzein catalyzed by dihydrodaidzein racemase.



**Figure 14.**

a) Intestinal microbial transformation of daidzein to *O*-desmethylangolensin (*O*-DMA) according to Joannou et al. 1995 (Joannou, Kelly, Reeder et al., 1995). b) Structure of (-)-(*R*)-*O*-desmethylangolensin.

Table 1

Functional capacity of gut microbes with relevance to polyphenol metabolism

Metabolic conversion substrate	Enzyme	UniProt Entry	Microbe species/taxon	References
<i>Carbon-carbon cleavage</i>				
C-ring cleavage cyanidin	-			(Aura, Martin-Lopez, O'Leary et al., 2005)
C-ring cleavage quercetin	Quercetin 2,3-dioxygenase (Flavonol 2,4-dioxygenase, Quercetinase)	P42106	<i>Bacillus subtilis</i> strain 168	(Bowater, Fairhurst, Just et al., 2004; Fetzner, 2012; Hirooka, Fujita, 2010; Hong, Khaneja, Tam et al., 2009; Schaab, Barney, Francisco, 2006)
A-ring cleavage catechin	-			(Appeldoorn, Vincken, Aura et al., 2009)
C-ring cleavage catechin	dioxygenases			(Gonthier, Cheynier, Donovan et al., 2003)
<i>Dehydroxylation of polyphenols</i>				
Ellagic acid			<i>Gordonibacter urolithinifaciens</i>	(Selma, Beltran, Garcia-Villalba et al., 2014; Selma, Tomas-Barberan, Beltran et al., 2014)
			<i>Clostridium coccooides</i>	(Garcia-Villalba, Beltran, Espin et al., 2013)
<i>Hydrogenations of alkene, enone and keto moieties</i>				
Curcumin	NADPH-dependent curcumin/dihydrocurcumin reductase (CurA)	P76113	<i>E. coli</i> strain K12	(Bowater, Fairhurst, Just et al., 2004; Hassaninasab, Hashimoto, Tomita-Yokotani et al., 2011)
Resveratrol			<i>Slackia equolifaciens</i> <i>Adlercreutzia equolifaciens</i>	(Bode, Bunzel, Huch et al., 2013)

Metabolic conversion substrate	Enzyme	UniProt Entry	Microbe species/taxon	References
Daidzin	Daidzein reductase	M9NZ71	<i>Slackia isoflavoniconvertens</i> strain HE8	(Schroder, Matthies, Engst et al., 2013)
		H3JUE4	<i>Slackia</i> sp. strain NATTS	(Tsuji, Moriyama, Nomoto et al., 2012)
		F7V1S0	<i>Eggerthella</i> sp. strain YY7918	(Yokoyama, Oshima, Nomura et al., 2011)
		S6CG95 *	<i>Adlercreutzia equolifaciens</i> strain DSM 19450	(Toh, Oshima, Suzuki et al., 2013)
		E1CIA4	<i>Lactococcus garvieae</i> ( <i>Lactococcus</i> sp. strain 20-92)	(Shimada, Yasuda, Takahashi et al., 2010)
Dihydrodaidzein	Dihydrodaidzein reductase	M9NYU8	<i>Slackia isoflavoniconvertens</i> strain HE8	(Schroder, Matthies, Engst et al., 2013)
		H3JUE3	<i>Slackia</i> sp. strain NATTS	(Tsuji, Moriyama, Nomoto et al., 2012)
		F7V1S2 *	<i>Eggerthella</i> sp. strain YY7918	(Yokoyama, Oshima, Nomura et al., 2011)
			<i>Eggerthella</i> sp. strain <i>Julong 732</i>	(Kim, Kim, Han et al., 2009)
		S6CF26 *	<i>Adlercreutzia equolifaciens</i> strain DSM 19450	(Toh, Oshima, Suzuki et al., 2013)
	E7FL41	<i>Lactococcus garvieae</i> ( <i>Lactococcus</i> sp. strain 20-92)	(Shimada, Takahashi, Miyazawa et al., 2011)	
Tetrahydrodaidzein	Tetrahydrodaidzein reductase	M9P0B3	<i>Slackia isoflavoniconvertens</i> strain HE8	(Schroder, Matthies, Engst et al., 2013)
		H3JUE2	<i>Slackia</i> sp. strain NATTS	(Tsuji, Moriyama, Nomoto et al., 2012)
		F7V1S3 *	<i>Eggerthella</i> sp. strain YY7918	(Yokoyama, Oshima, Nomura et al., 2011)
		S6CLL1 *	<i>Adlercreutzia equolifaciens</i> strain DSM 19450	(Toh, Oshima, Suzuki et al., 2013)

Metabolic conversion substrate	Enzyme	UniProt Entry	Microbe species/taxon	References
		E7FL40	<i>Lactococcus garvieae</i> ( <i>Lactococcus</i> sp. strain 20-92)	(Shimada, Takahashi, Miyazawa et al., 2011)
2-Dehydro- <i>O</i> -desmethylangolensin	-	-	<i>Eubacterium ramulus</i>	(Schoefer, Mohan, Braune et al., 2002)
			<i>E. ramulus</i> strain Julong 601	(Wang, Kim, Lee et al., 2004)
			<i>Clostridium</i> sp. strain HGH 136	(Hur, Beger, Heinze et al., 2002)
<b>Racemization</b>				
Dihydrodaidzein	Dihydrodaidzein racemase	I7H868	<i>Lactococcus garvieae</i> ( <i>Lactococcus</i> sp. strain 20-92)	(Shimada, Takahashi, Miyazawa et al., 2012)
		F7UU46*	<i>Eggerthella</i> sp. strain YY7918	(Yokoyama, Oshima, Nomura et al., 2011)
			<i>Eggerthella</i> sp. strain Julong 732	(Kim, Kim, Han et al., 2009)
		M9NZB2*	<i>Slackia isoflavoniconvertens</i> strain HE8	(Schroder, Matthies, Engst et al., 2013)
		S6C2M3*	<i>Adlercreutzia equolifaciens</i> strain DSM 19450	(Toh, Oshima, Suzuki et al., 2013)

\* putative, uncharacterized protein

**Table 2**

Amino acid sequence similarity between the enzymes involved in the biosynthetic transformation of daidzein to (*S*)-equol in the human intestinal microflora. Identity values were obtained by aligning the amino acid sequences of the enzymes of *S. isoflavoniconvertens* using the BLAST online tool.

Bacterial strain	Sequence homology using the <i>S. isoflavoniconvertens</i> enzymes as reference UniProt entry (% identity)		
	DZNR	DHDR	THDR
<i>Slackia isoflavoniconvertens</i> <sup>a</sup>	M9NZ71 (100)	M9NYU8 (100)	M9P0B3 (100)
<i>Slackia</i> sp.strain NATTS <sup>a</sup>	H3JUE4 (95)	H3JUE3 (96)	H3JUE2 (90)
<i>Eggerthella</i> sp. strain YY7918 <sup>a</sup>	F7V1S0 (43)	F7V1S2 <sup>c</sup> (87)	F7V1S3 <sup>c</sup> (87)
<i>Adlercreutzia equolifaciens</i> strain DSM 19450 <sup>a</sup>	S6CG95 <sup>c</sup> (43)	S6CF26 <sup>c</sup> (82)	S6CLL1 <sup>c</sup> (70)
<i>Lactococcus garvieae</i> <sup>b</sup>	E1CIA4 (43)	E7FL41 (87)	E7FL40 (87)

Taxonomy (class):

<sup>a</sup> Coriobacteria

<sup>b</sup> Bacilli

<sup>c</sup> putative, amino acid sequence deduced from gene sequence

**Table 3**

Protein functional motifs and classification of the principal reductases involved in the conversion of daidzein to (*S*)-equol (Schroder, Matthies, Engst et al., 2013)

Enzyme	Proposed Classification	Functional sequence motifs
Daidzein reductase (DZNR)	Old yellow enzyme (OYE) family; NADH:flavin oxidoreductase family (Karplus, Fox, Massey, 1995)	CX <sub>2</sub> CX <sub>3</sub> CX <sub>12</sub> C: 4Fe-4S cluster binding motif hhhXGXGX <sub>2</sub> GXE (where h is a hydrophobic residue): extended dinucleotide binding motif
Dihydrodaidzein reductase (DHDR)	“Classical” short-chain dehydrogenases/reductase (SDR) family (Kavanagh, Jornvall, Persson et al., 2008; Oppermann, Filling, Hult et al., 2003)	YX <sub>3</sub> K : catalytic tetrad TGX <sub>3</sub> GXG: conserved dinucleotide-binding motif;
Tetrahydrodaidzein reductase (THDR)	Glycyl radical enzyme family (Buckel, Golding, 2006; Shisler, Broderick, 2014)	GXGX <sub>2</sub> G: N-terminal dinucleotide-binding motif RVXG: glycyl radical enzyme motif